AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36807512 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated Balloon (PCB)
Number of subjects: 402
Study 36807512 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting Stent (PES)
Number of subjects: 402
Study 36807682 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of cervical spinal circuits (29 days, two linear leads in the dorsolateral epidural space targeting spinal roots C3 to T1)
Number of subjects: 2
Study 36807682 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous stimulation through selected contacts
Number of subjects: 2
Study 36807834 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental burden evaluated with the Experience of Caregiving Inventory
Number of subjects: 84
Study 36807834 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental grief evaluated with the Mental Illness Version of the Texas Revised Inventory of Grief
Number of subjects: 84
Study 36807834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' burden related to their own level of anxiety
Number of subjects: 84
Study 36807834 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal grief related to higher anxiety and depression
Number of subjects: 84
Study 36807834 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal grief correlated to higher alexithymia and depression
Number of subjects: 84
Study 36807834 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal burden explained by father's anxiety and grief
Number of subjects: 84
Study 36807834 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal burden explained by mother's grief and child's clinical state
Number of subjects: 84
Study 36808045 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive-behavioral therapy
Number of subjects: 17
Study 36808075 — intervention group
Group type: EXPERIMENTAL
Intervention: sitravatinib 120 mg orally once daily plus tislelizumab 200 mg intravenously every 3 weeks
Number of subjects: 122
Study 36808075 — intervention group
Group type: EXPERIMENTAL
Intervention: sitravatinib plus tislelizumab
Number of subjects: 122
Study 36808074 — intervention group
Group type: EXPERIMENTAL
Intervention: hCART19 therapy
Number of subjects: 58
Study 36808074 — intervention group
Group type: EXPERIMENTAL
Intervention: hCART19 therapy with consolidation therapy
Number of subjects: 58
Study 36808105 — intervention group
Group type: EXPERIMENTAL
Intervention: Croatian version of the Self-Evaluation of Communication Experiences after Laryngectomy questionnaire (SECEL:HR)
Number of subjects: 50
Study 36808105 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Handicap Index (VHI)
Number of subjects: 50
Study 36808105 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Form Health Survey (SF-36)
Number of subjects: 50
Study 36808105 — intervention group
Group type: EXPERIMENTAL
Intervention: SECEL:HR
Number of subjects: 50
Study 36808186 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (rifampin and isoniazid for 24 weeks with pyrazinamide and ethambutol for the first 8 weeks)
Number of subjects: 674
Study 36808186 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial rifampin-linezolid regimen
Number of subjects: 674
Study 36808186 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial bedaquiline-linezolid regimen
Number of subjects: 674
Study 36808216 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-g SCF + 600-mg calcium lactate gluconate (SCF + Ca)
Number of subjects: 243
Study 36808216 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-g SCF
Number of subjects: 243
Study 36808216 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg calcium lactate gluconate (Ca)
Number of subjects: 243
Study 36808216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 36808232 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic parameters assessed during the 6-min walk test (6MWT)
Number of subjects: 70
Study 36808239 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d
Number of subjects: 150
Study 36808239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 36808285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) 3 mg/kg every 2 weeks
Number of subjects: 166
Study 36808285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab (NIVO + IPI) 3 mg/kg + 1 mg/kg every 3 weeks (4 doses) followed by NIVO 3 mg/kg every 2 weeks
Number of subjects: 166
Study 36808596 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical interventions during postoperative period
Number of subjects: 200
Study 36808602 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 183
Study 36808602 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every week (qw)
Number of subjects: 183
Study 36808602 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 183
Study 36808602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 36808891 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg (oral)
Number of subjects: 8
Study 36808891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 100 μg of radiolabeled micro-tracer
Number of subjects: 8
Study 36808931 — intervention group
Group type: EXPERIMENTAL
Intervention: d-mannose (2 g/d)
Number of subjects: 32
Study 36808931 — intervention group
Group type: COMPARATOR
Intervention: Control (Vaginal Estrogen Therapy alone)
Number of subjects: 32
Study 36808953 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-mediated interventions, specifically video modeling for parental training.
Number of subjects: 37
Study 36808953 — intervention group
Group type: COMPARATOR
Intervention: Control group with no parental-training intervention.
Number of subjects: 37
Study 36809018 — intervention group
Group type: EXPERIMENTAL
Intervention: mSTART (Mobile SafeTy And Recovery Therapy)
Number of subjects: 78
Study 36809018 — intervention group
Group type: COMPARATOR
Intervention: START alone (without mobile augmentation)
Number of subjects: 78
Study 36809018 — intervention group
Group type: EXPERIMENTAL
Intervention: mSTART and START (regardless of mobile augmentation)
Number of subjects: 78
Study 36809019 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging in Community Roles and Experiences (EnCoRE)
Number of subjects: 36
Study 36809046 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 375
Study 36809046 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 + ET
Number of subjects: 375
Study 36809046 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab + ET
Number of subjects: 375
Study 36809050 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib (600 mg once daily) and Durvalumab (1,500 mg once every four weeks)
Number of subjects: 41
Study 36809050 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib and Durvalumab in MET-driven patients
Number of subjects: 41
Study 36809050 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib and Durvalumab in PD-L1-positive tumors
Number of subjects: 41
Study 36809050 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib and Durvalumab
Number of subjects: 41
Study 36809077 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-Infrared Imaging of Indocyanine Green
Number of subjects: 0
Study 36809080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus pemetrexed and platinum
Number of subjects: 0
Study 36809080 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36809150 — intervention group
Group type: EXPERIMENTAL
Intervention: Serdexmethylphenidate/Dexmethylphenidate Capsules
Number of subjects: 0
Study 36809187 — intervention group
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Number of subjects: 0
Study 36809187 — intervention group
Group type: COMPARATOR
Intervention: Control group outcomes not specified
Number of subjects: 0
Study 36809193 — intervention group
Group type: EXPERIMENTAL
Intervention: E4 15 mg
Number of subjects: 257
Study 36809193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 36809195 — intervention group
Group type: EXPERIMENTAL
Intervention: Setanaxib 400 mg twice daily (BID)
Number of subjects: 111
Study 36809195 — intervention group
Group type: EXPERIMENTAL
Intervention: Setanaxib 400 mg once daily (OD)
Number of subjects: 111
Study 36809195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 36809195 — intervention group
Group type: EXPERIMENTAL
Intervention: Setanaxib 400 mg BID (moderate-to-severe fatigue at baseline)
Number of subjects: 111
Study 36809195 — intervention group
Group type: EXPERIMENTAL
Intervention: Setanaxib 400 mg BID (mild fatigue at baseline)
Number of subjects: 111
Study 36809199 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional clinical trials related to GBS
Number of subjects: 21
Study 36809199 — intervention group
Group type: EXPERIMENTAL
Intervention: Completed trials
Number of subjects: 21
Study 36809199 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials in early phases (1 and 2)
Number of subjects: 21
Study 36809199 — intervention group
Group type: EXPERIMENTAL
Intervention: Average trial duration
Number of subjects: 21
Study 36809247 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-administered pre-referral rectal artesunate (RAS)
Number of subjects: 7983
Study 36809247 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral antimalarial and ACT administration
Number of subjects: 7983
Study 36809247 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT administration at discharge
Number of subjects: 7983
Study 36809247 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed treatment
Number of subjects: 7983
Study 36809247 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral artesunate not followed up with oral ACT
Number of subjects: 7983
Study 36809247 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-referral RAS
Number of subjects: 7983
Study 36809292 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIIT intervention
Number of subjects: 47
Study 36809294 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model using smartphone sensor data (XGBoost algorithm)
Number of subjects: 75
Study 36809321 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin discontinuation (intervention group) until delivery
Number of subjects: 936
Study 36809321 — intervention group
Group type: COMPARATOR
Intervention: Aspirin continuation (control group) until 36 weeks of gestation
Number of subjects: 936
Study 36809321 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of preterm preeclampsia incidences between groups
Number of subjects: 936
Study 36809338 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2max assessed by cardiopulmonary exercise test (CPET) using a logarithmic function of VO2max, height, and BMI.
Number of subjects: 1141
Study 36809338 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2max Z-score model
Number of subjects: 1141
Study 36809402 — intervention group
Group type: EXPERIMENTAL
Intervention: Visiodol (tactile pain evaluation scale)
Number of subjects: 37
Study 36809426 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium 68 scanning
Number of subjects: 50
Study 36809495 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 555
Study 36809495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 36809503 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO cohort
Number of subjects: 43
Study 36809503 — intervention group
Group type: COMPARATOR
Intervention: retrospective cohort
Number of subjects: 43
Study 36809647 — intervention group
Group type: EXPERIMENTAL
Intervention: Excitatory rTMS
Number of subjects: 37
Study 36809647 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory rTMS
Number of subjects: 37
Study 36809647 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 37
Study 36809647 — intervention group
Group type: EXPERIMENTAL
Intervention: F/M amplitude ratio
Number of subjects: 37
Study 36809645 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atropine (HDA)
Number of subjects: 11617
Study 36809645 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose atropine (MDA)
Number of subjects: 11617
Study 36809645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose atropine (LDA)
Number of subjects: 11617
Study 36809645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzipine
Number of subjects: 11617
Study 36809645 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal soft contact lenses (MFSCL)
Number of subjects: 11617
Study 36809645 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral plus spectacles (PPSL)
Number of subjects: 11617
Study 36809645 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal spectacles
Number of subjects: 11617
Study 36809645 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratology
Number of subjects: 11617
Study 36809645 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas-permeable contact lenses (RGP)
Number of subjects: 11617
Study 36809645 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-methylxanthine
Number of subjects: 11617
Study 36809645 — intervention group
Group type: EXPERIMENTAL
Intervention: Undercorrected single vision spectacles (SVLs)
Number of subjects: 11617
Study 36809645 — intervention group
Group type: COMPARATOR
Intervention: Inactive control
Number of subjects: 11617
Study 36809852 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (30 g); TID of AAs in whey was 97% ± 2.4% in humans and 97% ± 1.9% in pigs; if free AAs absorbed, TID would increase by 0.4%-units in humans and 0.1%-units in pigs.
Number of subjects: 20
Study 36809852 — intervention group
Group type: EXPERIMENTAL
Intervention: Zein protein; TID of AAs in zein was 70% ± 16.4% in humans and 77% ± 20.6% in pigs; if free AAs absorbed, TID would increase by 2.3%-units in humans and 3.5%-units in pigs.
Number of subjects: 20
Study 36809852 — intervention group
Group type: EXPERIMENTAL
Intervention: Free threonine from zein; if absorbed, TID would increase by 6.6%-units in both species (P < 0.05).
Number of subjects: 20
Study 36809852 — intervention group
Group type: COMPARATOR
Intervention: No-protein diet; used as a control in the pig study.
Number of subjects: 20
Study 36810069 — intervention group
Group type: EXPERIMENTAL
Intervention: MINISTOP 2.0 app
Number of subjects: 552
Study 36810069 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 552
Study 36810101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid balance control strategy (daily weight-driven restriction of fluid intake, diuretics administration, ultrafiltration if renal replacement therapy)
Number of subjects: 1353
Study 36810101 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1353
Study 36810101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid balance control strategy
Number of subjects: 1353
Study 36810100 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (8 hours sleep deficit)
Number of subjects: 24
Study 36810100 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation (8 hours sleep deficit)
Number of subjects: 24
Study 36810100 — intervention group
Group type: COMPARATOR
Intervention: Control (16/8 h wake/sleep regime)
Number of subjects: 24
Study 36810100 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving performance
Number of subjects: 24
Study 36810100 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor vigilance test
Number of subjects: 24
Study 36810100 — intervention group
Group type: EXPERIMENTAL
Intervention: d2 Test of Attention
Number of subjects: 24
Study 36810100 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual attention test
Number of subjects: 24
Study 36810100 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective (situational) sleepiness
Number of subjects: 24
Study 36810100 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalographic changes
Number of subjects: 24
Study 36810100 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral markers of sleepiness
Number of subjects: 24
Study 36810100 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in metabolite concentrations in exhaled breath and finger sweat
Number of subjects: 24
Study 36810100 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of metabolic changes among biological matrices
Number of subjects: 24
Study 36810120 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Prolonged Exposure (mPE) therapy plus Treatment as Usual (TAU)
Number of subjects: 22
Study 36810120 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 22
Study 36810163 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR)
Number of subjects: 42
Study 36810166 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrapyloric (No. 206) lymph node dissection
Number of subjects: 427
Study 36810166 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater curvature (No. 204) lymph node dissection
Number of subjects: 427
Study 36810166 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete mesocolic excision with central vascular ligation
Number of subjects: 427
Study 36810168 — intervention group
Group type: COMPARATOR
Intervention: Standard patient therapeutic education programme (control group)
Number of subjects: 80
Study 36810168 — intervention group
Group type: EXPERIMENTAL
Intervention: Vik-Asthme chatbot-guided training (experimental group)
Number of subjects: 80
Study 36810173 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship based on daily clinical assessment of clinical cure, allowing discontinuation of antibiotic therapy when at least three criteria of clinical cure are met.
Number of subjects: 590
Study 36810173 — intervention group
Group type: COMPARATOR
Intervention: Standard management with a fixed duration of appropriate antibiotic therapy for 7 days according to international guidelines.
Number of subjects: 590
Study 36810189 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol
Number of subjects: 0
Study 36810189 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 0
Study 36810194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (400 mcg/kg) administered monthly for 3 months
Number of subjects: 0
Study 36810194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (400 mcg/kg) plus livestock treatment with injectable ivermectin (200 mcg/kg) monthly for 3 months
Number of subjects: 0
Study 36810194 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg) monthly for 3 months
Number of subjects: 0
Study 36810250 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (cycling)
Number of subjects: 58
Study 36810250 — intervention group
Group type: COMPARATOR
Intervention: Stretching (active control group)
Number of subjects: 58
Study 36810360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intrapulmonary deflation
Number of subjects: 20
Study 36810360 — intervention group
Group type: COMPARATOR
Intervention: Positive expiratory pressure (PEP) therapy
Number of subjects: 20
Study 36810437 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 61
Study 36810437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 36810609 — intervention group
Group type: EXPERIMENTAL
Intervention: App-delivered mindfulness program for anxiety for two months
Number of subjects: 63
Study 36810609 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 63
Study 36810778 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support
Number of subjects: 702
Study 36810778 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support through saving attitudes
Number of subjects: 702
Study 36810778 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support through communication with guardian
Number of subjects: 702
Study 36810788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab or TNF inhibitor (TNFi)
Number of subjects: 929
Study 36810939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine-based regimens (most common dose 3 to 3.9 mcg/kg)
Number of subjects: 578
Study 36810939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine-based regimens
Number of subjects: 578
Study 36810945 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glucocorticoids (≤ 7.5mg/day prednisone)
Number of subjects: 1078
Study 36810959 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF/VEGFR targeting
Number of subjects: 0
Study 36810959 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel splice variants of VEGF
Number of subjects: 0
Study 36810986 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic PD catheter insertion
Number of subjects: 670
Study 36810986 — intervention group
Group type: COMPARATOR
Intervention: Medical insertion technique (percutaneous and peritoneoscopic)
Number of subjects: 670
Study 36811175 — intervention group
Group type: EXPERIMENTAL
Intervention: Glepaglutide (long-acting GLP-2 analog)
Number of subjects: 16
Study 36811311 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1, OXM, PYY (GOP) infusion for 4 weeks
Number of subjects: 24
Study 36811382 — intervention group
Group type: EXPERIMENTAL
Intervention: WNT974 + encorafenib + cetuximab (COMBO10: 10 mg, COMBO7.5: 7.5 mg, COMBO5: 5 mg)
Number of subjects: 20
Study 36811382 — intervention group
Group type: EXPERIMENTAL
Intervention: WNT974 + encorafenib + cetuximab
Number of subjects: 20
Study 36811462 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored intervention
Number of subjects: 0
Study 36811468 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy low-carbohydrate diet (LCD)
Number of subjects: 609
Study 36811468 — intervention group
Group type: COMPARATOR
Intervention: Healthy low-fat diet (LFD)
Number of subjects: 609
Study 36811468 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (LCD and LFD)
Number of subjects: 609
Study 36811468 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker of carbohydrate (triglyceride/HDL cholesterol ratio)
Number of subjects: 609
Study 36811474 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% cellular chickpea powder (CCP) bread
Number of subjects: 20
Study 36811474 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% cellular chickpea powder (CCP) bread
Number of subjects: 20